Evidence-based recommendations on cilostazol (Pletal), naftidrofuryl oxalate (Praxilene), pentoxifylline (Trental 400) and inositol nicotinate (Hexopal)
Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
Evidence-based recommendations on rituximab (MabThera) for the maintenance treatment of follicular non-Hodgkin’s lymphoma in adults
Evidence-based recommendations on peginterferon alfa (2a [Pegasys] or 2b [ViraferonPeg]) and ribavirin (Copegus or Rebetol) for treating chronic hepatitis C
Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women
NICE is unable to make a recommendation about the use in the NHS of bendamustine for treating indolent (low grade) non-Hodgkin's lymphoma that is refractory
NICE is unable to make a recommendation about the use in the NHS of temsirolimus for treating relapsed or refractory mantle cell lymphoma because no evidence
Evidence-based recommendations on trastuzumab (Herceptin) for treating adenocarcinoma (HER2-positive metastatic gastric cancer/stomach cancer)
Evidence-based recommendations on imatinib (Glivec) for treating unresectable (inoperable) and/or metastatic gastrointestinal stromal tumours (GISTs)
Evidence-based recommendations on clopidogrel (Plavix) and modified-release dipyridamole (Persantin/Asasantin Retard) for preventing occlusive vascular events
Evidence-based recommendations on prucalopride (Resolor) for treating chronic constipation in women
Evidence-based recommendations on bevacizumab (Avastin) with oxaliplatin and fluorouracil plus folinic acid or capecitabine for metastatic colorectal cancer
Evidence-based recommendations on erlotinib (Tarceva) for treating non-small-cell lung cancer (NSCLC)
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema secondary to retinal vein occlusion
Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.
NICE is unable to make a recommendation about the use in the NHS of agomelatine for major depressive episodes because no evidence submission was received
Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer
Evidence-based recommendations on capecitabine for treating advanced gastric cancer in adults
Evidence-based recommendations on gefitinib (Iressa) for the first-line treatment of advanced or metastatic non-small-cell lung cancer (NSCLC)
Evidence-based recommendations on rituximab (MabThera) for treating relapsed or refractory chronic lymphocytic leukaemia (CLL)
Evidence-based recommendations on azacitidine (Vidaza) for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis
Evidence-based recommendations on aripiprazole (Abilify) for treating moderate to severe manic episodes in adolescents with bipolar I disorder
Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune (idiopathic) thrombocytopenic purpura (chronic ITP)
NICE is unable to make a recommendation about the use in the NHS of decitabine for the treatment of acute myeloid leukaemia because no evidence...
Evidence-based recommendations on vinflunine (Javlor) for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract
NICE is unable to make a recommendation about the use in the NHS of tadalafil for treating symptoms associated with benign prostatic hyperplasia...
Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema
Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (AF)
Evidence-based recommendations on colistimethate sodium and tobramycin dry powders for inhalation for pseudomonas lung infection in cystic fibrosis
NICE is unable to recommend the use in the NHS of methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness...
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma
Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for osteoporotic vertebral compression fractures
NICE is unable to recommend the use in the NHS of canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks
Evidence-based recommendations on ranibizumab (Lucentis) for treating sight problems caused by macular oedema secondary to retinal vein occlusion
Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in atrial fibrillation (AF)
Evidence-based recommendations on fingolimod (Gilenya) for treating highly active relapsing–remitting multiple sclerosis (MS)
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in atrial fibrillation (AF)
Evidence-based recommendations on lapatinib (Tyverb) or trastuzumab (Herceptin) combined with an aromatase inhibitor for the first-line treatment of..
Evidence-based recommendations on erlotinib (Tarceva) for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults who have had previous treatment with a
Evidence-based recommendations on botulinum toxin type A (Botox) for the prevention of headaches in adults with chronic migraine
Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing recurrent DVT and pulmonary embolism
Evidence-based recommendations on bevacizumab (Avastin) in combination with capecitabine for the first-line treatment of metastatic breast cancer
Evidence-based recommendations on alteplase (Actilyse) for treating acute ischaemic stroke (AIS)
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours
NICE is unable to recommend the use in the NHS of panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer..
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination
Evidence-based recommendations on rituximab (MabThera) for the first-line treatment of stage III–IV follicular lymphoma